Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 (Onfasprodil) SC in Treatment-Resistant Depression
NCT05454410Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of onfasprodil in treatment-resistant depression (TRD) (4 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 hours. Started Mar 2023; status: completed.
02
Drugs
onfasprodil
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05454410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454410.